4ugf: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
+==Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-((((3S, 5R)-5-(((6-amino-4-methylpyridin-2-yl)methoxy)methyl) pyrrolidin-3-yl)oxy)methyl)-4-methylpyridin-2-amine==
+<StructureSection load='4ugf' size='340' side='right' caption='[[4ugf]], [[Resolution|resolution]] 1.81&Aring;' scene=''>
+== Structural highlights ==
+<table><tr><td colspan='2'>[[4ugf]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UGF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UGF FirstGlance]. <br>
+</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=H4B:5,6,7,8-TETRAHYDROBIOPTERIN'>H4B</scene>, <scene name='pdbligand=HEM:PROTOPORPHYRIN+IX+CONTAINING+FE'>HEM</scene>, <scene name='pdbligand=POL:N-PROPANOL'>POL</scene>, <scene name='pdbligand=Q16:6-((((3S,+5R)-5-(((6-AMINO-4-METHYLPYRIDIN-2-YL)METHOXY)METHYL)PYRROLIDIN-3-YL)OXY)METHYL)-4-METHYLPYRIDIN-2-AMINE'>Q16</scene></td></tr>
+<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ug5|4ug5]], [[4ug6|4ug6]], [[4ug7|4ug7]], [[4ug8|4ug8]], [[4ug9|4ug9]], [[4uga|4uga]], [[4ugb|4ugb]], [[4ugc|4ugc]], [[4ugd|4ugd]], [[4uge|4uge]], [[4ugg|4ugg]], [[4ugh|4ugh]], [[4ugi|4ugi]], [[4ugj|4ugj]], [[4ugk|4ugk]], [[4ugl|4ugl]], [[4ugm|4ugm]], [[4ugn|4ugn]], [[4ugo|4ugo]], [[4ugp|4ugp]], [[4ugq|4ugq]], [[4ugr|4ugr]], [[4ugs|4ugs]], [[4ugt|4ugt]], [[4ugu|4ugu]], [[4ugv|4ugv]], [[4ugw|4ugw]], [[4ugx|4ugx]], [[4ugy|4ugy]]</td></tr>
+<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Nitric-oxide_synthase_(NAD(P)H-dependent) Nitric-oxide synthase (NAD(P)H-dependent)], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.14.13.165 1.14.13.165] </span></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ugf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ugf OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ugf RCSB], [http://www.ebi.ac.uk/pdbsum/4ugf PDBsum]</span></td></tr>
+</table>
+== Function ==
+[[http://www.uniprot.org/uniprot/NOSO_BACSU NOSO_BACSU]] Catalyzes the production of nitric oxide.
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+Nitric oxide generated by bacterial nitric oxide synthase (NOS) increases the susceptibility of Gram-positive pathogens Staphylococcus aureus and Bacillus anthracis to oxidative stress, including antibiotic-induced oxidative stress. Not surprisingly, NOS inhibitors also improve the effectiveness of antimicrobials. Development of potent and selective bacterial NOS inhibitors is complicated by the high active site sequence and structural conservation shared with the mammalian NOS isoforms. To exploit bacterial NOS for the development of new therapeutics, recognition of alternative NOS surfaces and pharmacophores suitable for drug binding is required. Here, we report on a wide number of inhibitor-bound bacterial NOS crystal structures to identify several compounds that interact with surfaces unique to the bacterial NOS. Although binding studies indicate that these inhibitors weakly interact with the NOS active site, many of the inhibitors reported here provide a revised structural framework for the development of new antimicrobials that target bacterial NOS. In addition, mutagenesis studies reveal several key residues that unlock access to bacterial NOS surfaces that could provide the selectivity required to develop potent bacterial NOS inhibitors.
-The entry 4ugf is ON HOLD  until Paper Publication
+Inhibitor Bound Crystal Structures of Bacterial Nitric Oxide Synthase.,Holden JK, Dejam D, Lewis MC, Huang H, Kang S, Jing Q, Xue F, Silverman RB, Poulos TL Biochemistry. 2015 Jun 23. PMID:26062720<ref>PMID:26062720</ref>
-Authors: Holden, J.K., Poulos, T.L.
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+</div>
-Description: Structure of Bacillus subtilis Nitric Oxide Synthase in complex with 6-((((3S, 5R)-5-(((6-amino-4-methylpyridin-2-yl)methoxy)methyl) pyrrolidin-3-yl)oxy)methyl)-4-methylpyridin-2-amine
+== References ==
-[[Category: Unreleased Structures]]
+<references/>
-[[Category: Poulos, T.L]]
+__TOC__
-[[Category: Holden, J.K]]
+</StructureSection>
+[[Category: Holden, J K]]
+[[Category: Poulos, T L]]
+[[Category: Inhibitor]]
+[[Category: Nitric oxide synthase]]
+[[Category: Oxidoreductase]]